Association Of Increased Survival In Glioblastoma Patients Treated With Dendritic Cell Vaccinations And Temozolomide With Increased Activity Of Nk Cells And Abcc3 Expression.

2039Background: In the two stage phase I-II study DENDR-I, 24 patients with first diagnosis of glioblastoma (GBM) were treated with DC immunotherapy associated to standard radio-chemotherapy. To go to stage II progression-free survival (PFS) 12 months after surgery (PFS-12) was expected in at least 8 cases. Evidence of immune response was investigated. Methods: Patients with post-surgery volume ≤ 10 cc underwent leukapheresis before radiotherapy and chemotherapy with temozolomide (TMZ). Three intradermal injections of mature DC loaded with whole tumor lysate were done before and four after adjuvant TMZ. Results: The treatment was well tolerated. After a median follow up of 18.8 months 10 patients reached PFS12 (responders). Median overall survival (OS) was 19.4 mo comparing favorably with OS expected using the EORTC nomogram model 3 of 13.0 mo (p = 0.01). The immune activation of effector cells was assessed by intracellular staining of interferon-gamma (IFN-γ) in PBLs of 5 responders and 6 non-responders....